What do dopamine transporter and catechol-o-methyltransferase tell us about attention deficit–hyperactivity disorder? Pharmacogenomic implications

References

• Barkley RA. ADHD and the nature of self-control. Guilford Press, New York 1997
   Google Scholar
• Sonuga-Barke EJS. The dual pathway model of AD/HD: an elaboration of neuro-developmental characteristics. Neurosci Biobehav Rev 2003; 27: 593–604
   PubMed Web of Science ®Google Scholar
• Sagvolden T, Johansen EB, Aase H, Russell VA. A dynamic developmental theory of attention deficit hyperactivity disorder (ADHD) predominantly hyperactive/impulsive subtype. Behav Brain Sci 2005; 28: 397–468
   PubMed Web of Science ®Google Scholar
• Hay DA, McStephen M, Levy F. The developmental genetics of ADHD. Attention genes and ADHD, F Levy, DA Hay. Brunner-Routledge, Philadelphia, PA 2001; 66–68
   Google Scholar
• Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–1323
   PubMed Web of Science ®Google Scholar
• Kirley A, Hawi Z, Daly G, et al. Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 2002; 27: 607–619
   PubMed Web of Science ®Google Scholar
• Volkow, ND, Wang, G-J, Fowler, JSet al.Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: RC121.
   Web of Science ®Google Scholar
• Cook EH, Stein MA, Krasowski MD, et al. Association of attention deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995; 56: 993–998
   PubMed Web of Science ®Google Scholar
• Curran S, Mill J, Tahir E, et al. Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol Psychiatry 2001; 6: 425–428
   PubMed Web of Science ®Google Scholar
• Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-o-methyltransferase polymorphism: relations to the tonic–phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology 2004; 29: 1943–1961
   PubMed Web of Science ®Google Scholar
• McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005; 57: 1367–1373
   PubMed Web of Science ®Google Scholar
• Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999; 38: 1474–1477
   PubMed Web of Science ®Google Scholar
• Roman T, Szobot C, Martine S, Biederman J, Rohde LA, Hutz MH. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 2002; 12: 497–499
   PubMedGoogle Scholar
• Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 2004; 74: 1–57
   PubMed Web of Science ®Google Scholar
• Kirley A, Lowe N, Hawi A, et al. Association of the 480 bp DAT1 with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet 2003; 121B: 50–54
   PubMed Web of Science ®Google Scholar
• Hamarman S, Fossella J, Ulger C, Brimacombe M, Dermody J. Dopamine receptor4 (DRD4) 7 repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2004; 14: 564–574
   PubMed Web of Science ®Google Scholar
• Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1397–1409
   PubMed Web of Science ®Google Scholar
• Eisenberg J, Mei-Tal G, Steinberg A, et al. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet 1999; 88: 497–502
   PubMed Web of Science ®Google Scholar
• Barr CL, Wigg K, Malone M, et al. Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am J Med Genet 1999; 88: 710–713
   PubMed Web of Science ®Google Scholar
• Hawi Z, Millar N, Daly G, Fitzgerald M, Gill M. No association between catechol-O-methyltransferase (COMT) gene polymorphism and ADHD in an Irish sample. Am J Med Genet 2000; 96: 241–243
   PubMedGoogle Scholar
• Manor I, Kotler M, Sever Y, et al. Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. Am J Med Genet 2000; 96: 858–860
   PubMed Web of Science ®Google Scholar
• Payton A, Holmes J, Barrett JH, et al. Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study. Am J Med Genet 2001; 105: 464–470
   PubMed Web of Science ®Google Scholar
• Tahir E, Curran S, Yazgan Y, Ozbay F, Cirakoglu B, Asherson P. No association between low and high activity catecholamine-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 2000; 5: 396–404
   PubMed Web of Science ®Google Scholar
• Qian Q, Wang Y, Zhou R, et al. Family-based and case–control association studies of catechol-O-methyltransferase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet 2003; 118B: 103–109
   PubMed Web of Science ®Google Scholar
• Taerk, E, Grizenko, N, Ben Amor, L, et al. Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD. BMC Med Genet 2004; 5:30.
   PubMedGoogle Scholar
• Diamond A, Briand L, Fossella J, Gehlbach L. Genetic and neurochemical modulation of prefrontal cognitive functions in children. Am J Psychiatry 2004; 161: 125–132
   PubMed Web of Science ®Google Scholar
• Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val 158-met genotype and individual variation in brain response to amphetamine. Proc Natl Acad Sci USA 2003; 100: 6186–6191
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Kohn PD, Kolachana B, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci 2005; 8: 594–596
   PubMed Web of Science ®Google Scholar
• Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in dose effects on learning and social behavior. Science 1997; 198: 1274–1276
   Google Scholar
• Evans SW, Pelham WE. Psychostimulant effects on academic and behavioral measures for ADHD junior high school students in a lecture format classroom. J Abnorm Child Psychol 1991; 19: 537–52
   PubMed Web of Science ®Google Scholar
• Douglas VI, Barr RG, Desilets J, Sherman E. Do high doses of stimulants impair flexible thinking in Attention-Deficit Hyperactivity Disorder?. J Am Acad Child Adolesc Psychiatry 1994; 34: 877–885
   Web of Science ®Google Scholar
• Solanto MV, Wender EH. Neuropharmacological basis of stimulant drug action in attention deficit disorder with hyperactivity. Psychol Bull 1989; 26: 897–902
   Google Scholar
• Tannock R, Schachar R. Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry Allied Disc 1992; 33: 217–28
   Web of Science ®Google Scholar
• Floresco SB, West AR, Ash B, Moore H, Grace AA. Extrasynaptic dopamine and phasic neuronal activity. Nat Neurosci 2004; 7: 199
   PubMed Web of Science ®Google Scholar